First “smart pill” ready to hit the market

Otsuka’s Abilify MyCite, the only FDA-approved digital pill, has taken another step toward patients thanks to a deal with Magellan Health to distribute the medicine through its network of mental health providers.

The drug, which is approved to treat schizophrenia and bipolar disorder, is the electronic version of Abilify and is designed to help patients take their medication as directed and, if they choose, to enlist other people as well.

Abilify MyCite records the date and time a patient takes a pill and relays that information, along with activity level, to a personal smartphone app where patients can add information about their mood, sleep and other health stats. If the patient allows, the dosing info also goes to their healthcare providers and caregivers.

Click here to read the entire article.